Monte Rosa Therapeutics (GLUE) amends Form 144; RSU award and sales noted
Rhea-AI Filing Summary
Monte Rosa Therapeutics amended a Form 144 filing reporting restricted stock unit activity tied to compensation and subsequent sales by a reporting holder. The amendment lists 21,865 RSUs awarded on 01/02/2025 with a vesting/exercise-related date of 01/02/2026. The filing records dispositions by Markus Warmuth on 03/02/2026 and 04/14/2026 with reported transaction amounts of $97,974.22 and $141,124.80 respectively. The submission is an amended (144/A) notice dated 05/01/2026.
Positive
- None.
Negative
- None.
Insights
Amendment documents RSU award and resale notices under Form 144/A.
The amendment lists a 21,865 RSU award dated 01/02/2025 and identifies sales by a reporting holder on 03/02/2026 and 04/14/2026 with amounts of $97,974.22 and $141,124.80. This filing updates prior sale notices; it does not by itself state method of sale or purchaser.
Timing and mechanics of any resale (brokered block, private sale, or otherwise) are not described in the excerpt; subsequent filings or broker confirmations would specify execution details.
The disclosure shows compensation-related equity and insider dispositions, administrative in nature.
The record shows RSUs granted as Stock Award with a compensation purpose and two monetary disposition entries tied to Markus Warmuth. The amendment format suggests clerical or timing corrections rather than a new strategic action.
Investors seeking further context should consult transfer/transaction-level filings for method and whether proceeds went to the selling holder or issuer; that treatment is not included in the excerpt.